Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics has proposed, subject to shareholder approval, the issuance of 1,000,000 unlisted options to director Professor Ian Constable under its Long Term Incentive Plan, matching the vesting conditions and A$1.80 strike price of options previously granted to its chairman upon appointment. The move, detailed alongside a Change of Director Interest Notice, underscores the company’s continued use of equity-based incentives to align board members with long-term shareholder value as it advances its RNA therapy pipeline for genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing a new generation of RNA-based precision medicines for patients with genetic diseases that currently lack treatment options. Leveraging a proprietary drug delivery platform to enhance the potency of RNA therapies, the company targets monogenic diseases, a segment viewed as having a high likelihood of clinical development success within the rapidly expanding RNA therapeutics market.
Average Trading Volume: 452,666
Technical Sentiment Signal: Buy
Current Market Cap: A$974M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.